If you have been reading about dihexa and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-26. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
=== Other applications === In soil science, cation-exchange capacity is the ion-exchange capacity of soil for positively charged ions. Soils can be considered as natural weak cation exchangers. In pollution remediation and geotechnical engineering, ion-exchange capacity determines the swelling capacity of swelling or expansive clay such as montmorillonite, which can be used to "capture" pollutants and charged ions. In planar waveguide manufacturing, ion exchange is used to create the guiding layer of higher index of refraction. Dealkalization, removal of alkali ions from a glass surface. Chemically strengthened glass, produced by exchanging K+ for Na+ in soda glass surfaces using KNO3 melts.
SCH-79797 Vorapaxar, sold under the brand name Zontivity, is a first-in-class anti-platelet drug used in the treatment of heart disease in patients with a history of heart attacks and peripheral artery disease. Vorapaxar has been recently shown to attenuate the neutrophilic inflammatory response to Streptococcus pneumoniae by reducing levels of pro-inflammatory cytokines such as IL-1β and chemokines CXCL1, CCL2 and CCL7. PAR1 is inhibited by Vorapaxar when the molecule binds to a binding pocket between extracellular loop 2 and 3 of the PAR1 where it stabilizes the inactivated protein structure and prevents the switch to the active conformation.
Again there are a few anomalies along the way: for example, as single atoms neither actinium nor thorium actually fills the 5f subshell, and lawrencium does not fill the 6d shell, but all these subshells can still become filled in chemical environments. For a very long time, the seventh row was incomplete as most of its elements do not occur in nature. The missing elements beyond uranium started to be synthesized in the laboratory in 1940, when neptunium was made. (However, the first element to be discovered by synthesis rather than in nature was technetium in 1937.) The row was completed with the synthesis of tennessine in 2009 (the last element oganesson had already been made in 2002), and the last elements in this seventh row were given names in 2016.
Sources: en.wikipedia.org
The first trailers Compulsion released as well as the early access version, featuring a short narrative sequence introducing the playable character Arthur, created the impression that the game would be a first-person action-adventure game with a linear narrative. These early versions of We Happy Few were frequently compared to BioShock, a first-person shooter with a strong narrative produced by Irrational Games on a triple-A budget, and well outside the class of game that Compulsion was seeking to make. Compulsion maintained it was aiming to produce a roguelike survival game with some light narrative elements, which was meant to be played repeatedly, with a complete playthrough taking only three to four hours. Compulsion was aware that early access had worked well for games that lacked a strong narrative, and thus focused the initial development within early access on the survival elements, planning to hold back on the narrative development until late in the process as they did not want to reveal the full story until late in development. Compulsion also found it difficult to convince players that story elements were coming for the game's final release. Compulsion learned that players from early access were much more interested in the game's narrative over the game's survival or roguelike mechanics. At one point, the studio tried to remove the survival elements leaving only the action-adventure gameplay, but felt this affected the balance and flavor of the title, since Wellington Wells was meant to be a society on the verge of collapse due to dwindling resources.
While reef-forming corals are almost entirely restricted to warm and shallow marine waters, other cnidarians can be found at great depths, in polar regions, and in freshwater. Cnidarians are a very ancient phylum, with fossils having been found in rocks formed about 580 million years ago during the Ediacaran period, preceding the Cambrian Explosion. Other fossils show that corals may have been present shortly before 490 million years ago and diversified a few million years later. Molecular clock analysis of mitochondrial genes suggests an even older age for the crown group of cnidarians, estimated around 741 million years ago, almost 200 million years before the Cambrian period, as well as before any fossils. Recent phylogenetic analyses support monophyly of cnidarians, as well as the position of cnidarians as the sister group of bilaterians.
=== HLX === Following the release of Half-Life: Alyx in 2020, dataminers examining updates to the Source 2 engine discovered that Valve was developing a non-VR game codenamed HLX. On December 31, 2024, Mike Shapiro, the voice actor for the G-Man, posted a cryptic message on X suggesting "unexpected surprises" in the new year. In April, it was reported that HLX was being playtested and would be a sequel to Episode Two. Industry insiders, dataminers and leakers reported that Valve was planning a 2025 announcement for HLX. In December, the Insider Gaming senior editor Mike Straw said HLX was planned as a launch game for Valve's Steam Machine hardware, and the announcement had been delayed by the rising cost of RAM.
Laser spectroscopy (or cavity ring-down spectroscopy, CRDS) is able to directly measure 2H/1H, 17O/16O and 18O/16O isotopic composition in water or methane. The use of laser spectroscopy on hydrogen isotopes was first reported by Bergamaschi et al. in 1994. They directly measured 12CH3D/12CH4 in atmospheric methane using a lead salt tunable diode laser spectroscopy. The development of CRDS was first reported by O'Keefe et al. in 1988. In 1999, Kerstel et al. successfully applied this technique to determine HIC in water. The system consists of a laser and a cavity equipped with high finesse reflectivity mirrors. Laser light is injected into the cavity, where the resonance takes place due to the constructive interference. The laser then is turned off. The decay of light intensity is measured. In the presence of a water sample, the photo-absorption by water isotopologues follows the kinetic law. The optical spectrum is obtained by recording ring-down time of the H2O spectral features of interest at certain laser wavelength. The concentration of each isotopologue is proportional to the area under each measured isotopologue spectral feature. Laser spectroscopy is quick, simple, and relatively cheap; and the equipment is portable. So it can be used in the field for measuring water samples. 2H/1H and 18O/16O can be determined simultaneously from a single injection. It requires a small sample size, < 1 μL for water. Typical precision is ~ 1‰. However, this is a compound-specific instrument, i.e. only one specific compound can be measured. And coexisting organic compounds (i.e.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.